Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial

被引：27
|
作者：
Spaner, David E. [1 ,2 ,3 ,4 ,5 ]
Wang, Guizhei [1 ]
McCaw, Lindsay [1 ]
Li, Yanmei [1 ]
Disperati, Patricia [6 ]
Cussen, Mary-Ann [3 ]
Shi, Yonghong [1 ]
机构：
[1] Sunnybrook Res Inst, Biol Platform, Toronto, ON, Canada
[2] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada
[3] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[4] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada
[5] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A1, Canada
[6] Toronto East Gen Hosp, Toronto, ON, Canada
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 05期
关键词：
chronic lymphocytic leukemia; Janus Kinases; STAT3; Ruxolitinib; Ibrutinib; Kinase inhibitors; phosphoproteome; FOLLOW-UP; RESISTANCE; THERAPY; CELLS; CLL;
D O I：
10.3324/haematol.2015.135418
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial
    Spaner, David E.
    Luo, Yuxuan
    Wang, Guizhei
    Gallagher, Jennifer
    Tsui, Hubert
    Shi, Yonghong
    CANCER MEDICINE, 2021, 10 (24): : 8789 - 8798
  • [2] Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial
    Spaner, David E.
    McCaw, Lindsay
    Wang, Guizhei
    Tsui, Hubert
    Shi, Yonghong
    CANCER MEDICINE, 2019, 8 (04): : 1540 - 1550
  • [3] A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
    Pemmaraju, Naveen
    Kantarjian, Hagop
    Kadia, Tapan
    Cortes, Jorge
    Borthakur, Gautam
    Newberry, Kate
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Jabbour, Elias
    Dellasala, Sara
    Pierce, Sherry
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (03): : 171 - 176
  • [4] Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies
    Friedman, Daphne R.
    Lanasa, Mark C.
    Davis, Patricia H.
    Allgood, Sallie D.
    Matta, Karen M.
    Brander, Danielle M.
    Chen, Youwei
    Davis, Evan D.
    Volkheimer, Alicia D.
    Moore, Joseph O.
    Gockerman, Jon P.
    Sportelli, Peter
    Weinberg, J. Brice
    LEUKEMIA & LYMPHOMA, 2014, 55 (05) : 1067 - 1075
  • [5] Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
    Woyach, Jennifer Ann
    Flynn, Joseph M.
    Jones, Jeffrey Alan
    Andritsos, Leslie A.
    Lucas, Margaret
    Chase, Weihong
    Yang, Ying
    Lucas, David M.
    Sass, Ellen
    Waymer, Sharon
    Ling, Yonghua
    Jiang, Yao
    Phelps, Mitch A.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] A phase II trial of immune therapy for chronic lymphocytic leukemia.
    Saville, W
    Kipps, TJ
    Cantwell, MJ
    Rassenti, LZ
    Rieger, R
    Osborne, S
    Prussak, CE
    BLOOD, 2003, 102 (11) : 437A - 437A
  • [7] PHASE-II TRIAL OF TAMOXIFEN IN CHRONIC LYMPHOCYTIC-LEUKEMIA
    ALGAILANI, F
    MARDER, RJ
    RADOSEVICH, JA
    HAUCK, WW
    MOLTENI, A
    ROSEN, ST
    CANCER TREATMENT REPORTS, 1986, 70 (11): : 1343 - 1344
  • [8] Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial
    Ferrajoli, Alessandra
    Falchi, Lorenzo
    O'Brien, Susan
    Wierda, William
    Faderl, Stefan
    Smith, Susan C.
    Ayala, Ana B.
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2012, 120 (21)
  • [9] Combination of Ofatumumab and Lenalidomide In Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial
    Badoux, Xavier
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Yerrow, Kimberly
    Kantarjian, Hagop M.
    Keating, Michael J.
    Ferrajoli, Alessandra
    BLOOD, 2010, 116 (21) : 1023 - 1024
  • [10] Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis
    Verstovsek, Srdan
    POSTGRADUATE MEDICINE, 2013, 125 (01) : 128 - 135
12345